Qualigen Therapeutics Inc
General ticker "QLGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.7M
Qualigen Therapeutics Inc does not follow the US Stock Market performance with the rate: -41.6%.
Estimated limits based on current volatility of 3.8%: low 3.88$, high 4.19$
Factors to consider:
- Price in estimated range
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2022-12-31 to 2024-12-30
- 2022-12-31 to 2023-12-31 estimated range: [12.11$, 82.74$]
- 2023-12-31 to 2024-12-30 estimated range: [2.87$, 19.00$]
Financial Metrics affecting the QLGN estimates:
- Negative: Non-GAAP EPS, $ of -197.02 <= 0.10
- Negative: Operating profit margin, % of -81.65 <= 1.03
- Negative: Operating cash flow per share per price, % of -4.43 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -21.66 <= 3.85
- Negative: Industry earnings per price (median), % of -24.66 <= 1.31
Short-term QLGN quotes
Long-term QLGN plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 |
|---|---|---|
| Operating Revenue | $5.65MM | $4.98MM |
| Operating Expenses | $28.32MM | $27.16MM |
| Operating Income | $-22.66MM | $-22.18MM |
| Non-Operating Income | $4.77MM | $0.88MM |
| Interest Expense | $0.00MM | $0.03MM |
| R&D Expense | $11.72MM | $6.84MM |
| Income(Loss) | $-17.89MM | $-21.30MM |
| Taxes | $0.01MM | $-0.27MM |
| Profit(Loss) | $-17.90MM | $-21.03MM |
| Stockholders Equity | $16.56MM | $7.24MM |
| Inventory | $1.06MM | $1.59MM |
| Assets | $22.84MM | $19.08MM |
| Operating Cash Flow | $-14.73MM | $-13.25MM |
| Capital expenditure | $0.14MM | $0.32MM |
| Investing Cash Flow | $-0.14MM | $-0.18MM |
| Financing Cash Flow | $8.43MM | $2.91MM |
| Earnings Per Share* | $-6.10 | $-5.48 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.